Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
September 08, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
September 03, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 31, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting

Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation Initiation of Phase 3, placebo-controlled,...
August 28, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 20, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine

NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...
August 10, 2020 07:05 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

Two NDA submissions, for AXS-05 in MDD and for AXS-07 in migraine, on track for 4Q 2020 Enrollment completed for both the AXS-05 Phase 3 long-term safety trial in MDD, and for the AXS-07 Phase 3...
August 10, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program

Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020 Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD,...
August 05, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
July 30, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020

Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...